Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KBA 1412

Next Previous
Drug Profile

KBA 1412

Alternative Names: AT-1412; KBA-1412

Latest Information Update: 03 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AIMM Therapeutics
  • Developer Kling Biotherapeutics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Phagocyte stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours
  • Discontinued Multiple myeloma; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 24 Jul 2024 Kling Biotherapeutics completes a phase-Ib trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy, Combination therapy) in Belgium and Netherlands (IV), (NCT05501821)
  • 15 Aug 2022 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Netherlands (IV), after August 2022 (NCT05501821)
  • 15 Aug 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Netherlands (IV), after August 2022 (NCT05501821)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top